Related Experiment Videos
Expression of P-glycoprotein and C-MOAT in human hepatocellular carcinoma: detection by immunostaining
John Richart1, Elizabeth M Brunt, Adrian M Di Bisceglie
1Department of Internal Medicine, Saint Louis University School of Medicine, St Louis, Missouri 63104, USA.
Abstract:
P-Glycoprotein and C-MOAT are important hepatic transport proteins which play a role in handling anticancer drugs. Hepatocellular carcinoma is a common hepatic malignancy that is relatively resistant to chemotherapeutic drugs. We therefore studied the expression of these two transport proteins in liver sections from hepatocellular carcinoma by immunohistochemistry and compared the reactivity to that in other liver conditions, including cirrhosis and dysplasia. We studied 53 sections from 17 liver specimens and found that the majority of samples stained positively for both P-glycoprotein and C-MOAT; however, the degree of staining was less in HCC and hepatic adenoma than in liver adjacent to HCC or in cirrhosis or dysplastic nodules. HCC with a compact pattern had less staining than those with acinar, scirrhous, or trabecular patterns. The location of both P-glycoprotein and C-MOAT staining was a function of the liver lesion present. Thus, most tissues without hepatocellular carcinoma showed foci of globular canalicular staining, whereas a delicate linear pattern of canalicular staining was most common overall. We conclude that expression of P-glycoprotein and C-MOAT, as detected by qualitative immunohistochemical evaluation are little affected by the development of HCC and therefore are probably of little clinical significance for management of malignancy.
Insights
Expression of P-glycoprotein and C-MOAT, key hepatic transport proteins, is minimally affected by hepatocellular carcinoma (HCC). This suggests these proteins have limited clinical significance for managing this common liver malignancy.
Area of Science:
- Hepatology
- Oncology
- Molecular Biology
Background:
- P-glycoprotein and C-MOAT are crucial hepatic transport proteins involved in anticancer drug disposition.
- Hepatocellular carcinoma (HCC) frequently exhibits resistance to chemotherapy.
- Understanding transporter expression is vital for predicting drug response in liver cancer.
Purpose of the Study:
- To investigate the expression patterns of P-glycoprotein and C-MOAT in hepatocellular carcinoma.
- To compare transporter expression in HCC with other liver conditions like cirrhosis and dysplasia.
- To assess the clinical relevance of these transporters in HCC management.
Main Methods:
- Immunohistochemistry was employed to analyze liver sections from 17 specimens (53 sections).
- Expression and localization of P-glycoprotein and C-MOAT were evaluated.
- Reactivity was compared between HCC, adjacent liver tissue, cirrhosis, and dysplastic nodules.
Main Results:
- Most samples showed positive staining for both P-glycoprotein and C-MOAT.
- Staining intensity was reduced in HCC and hepatic adenoma compared to adjacent liver, cirrhosis, or dysplastic nodules.
- Specific staining patterns varied based on HCC histological type and lesion presence.
Conclusions:
- P-glycoprotein and C-MOAT expression are largely unaltered by HCC development.
- Qualitative immunohistochemical evaluation indicates limited clinical significance for these transporters in managing HCC.
- Further research may explore quantitative analysis or functional assays for transporter roles.